Journal
OPEN FORUM INFECTIOUS DISEASES
Volume 9, Issue 3, Pages -Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/ofid/ofac019
Keywords
otitis media; antibiotic use; pneumococcal conjugate vaccines
Categories
Funding
- Building Interdisciplinary Research Careers in Women's Health (BIRCWH) program - National Institutes of Health (NIH) [5K12HD043483]
- National Institute on Drug Abuse [K01DA051683]
- Sanofi Pasteur
- Vanderbilt Trans-Institutional Program Vanderbilt Study of Antimicrobial Resistance
- National Institutes of Health ([NIH] NIAID) [K24AI148459]
Ask authors/readers for more resources
The introduction of PCV13 vaccine led to reductions in otitis media among US children, but its impact on antibiotic use for otitis media remained stable among Tennessee children under 2 years of age.
Otitis media (OM) is a leading cause of pediatric antibiotic use. Introduction of the 13-valent pneumococcal conjugate vaccine (PCV13) led to reductions in OM among US children, though its impact on OM-related antibiotic use remains unclear. Among 499 683 Tennessee children <2 years of age, the OM-related antibiotic fill rate was stable after PCV13 introduction.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
